Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Decision Support Tools for Regenerative Medicine: Systematic Review.

Lam C, Meinert E, Alturkistani A, Carter AR, Karp J, Yang A, Brindley D, Cui Z.

J Med Internet Res. 2018 Dec 19;20(12):e12448. doi: 10.2196/12448.

2.

The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.

Hettle R, Corbett M, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, Palmer S.

Health Technol Assess. 2017 Feb;21(7):1-204. doi: 10.3310/hta21070.

3.

Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions.

Hassan S, Simaria AS, Varadaraju H, Gupta S, Warren K, Farid SS.

Regen Med. 2015;10(5):591-609. doi: 10.2217/rme.15.29. Erratum in: Regen Med. 2015 Nov;10(8):1045.

4.

Manufacturing challenges in regenerative medicine.

Martin I, Simmons PJ, Williams DF.

Sci Transl Med. 2014 Apr 16;6(232):232fs16. doi: 10.1126/scitranslmed.3008558.

PMID:
24739757
5.

Organ Chips: Quality Assurance Systems in Regenerative Medicine.

Pasqualini FS, Emmert MY, Parker KK, Hoerstrup SP.

Clin Pharmacol Ther. 2017 Jan;101(1):31-34. doi: 10.1002/cpt.527. Epub 2016 Nov 21.

6.

Potential Therapeutic Strategies of Regenerative Medicine for Renal Failure.

Mata-Miranda MM, Delgado-Macuil RJ, Rojas-Lopez M, Martinez-Flores R, Vazquez-Zapien GJ.

Curr Stem Cell Res Ther. 2017;12(5):423-431. doi: 10.2174/1574888X12666170317163416. Review.

PMID:
28322169
7.

An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol.

Pettitt D, Arshad Z, Davies B, Smith J, French A, Cole D, Bure K, Dopson S, DiGiusto D, Karp J, Reeve B, Barker R, Holländer G, Brindley D.

Syst Rev. 2017 Jun 26;6(1):120. doi: 10.1186/s13643-017-0517-4.

8.

Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies.

Simaria AS, Hassan S, Varadaraju H, Rowley J, Warren K, Vanek P, Farid SS.

Biotechnol Bioeng. 2014 Jan;111(1):69-83. doi: 10.1002/bit.25008. Epub 2013 Aug 16.

9.

Manufacturing road map for tissue engineering and regenerative medicine technologies.

Hunsberger J, Harrysson O, Shirwaiker R, Starly B, Wysk R, Cohen P, Allickson J, Yoo J, Atala A.

Stem Cells Transl Med. 2015 Feb;4(2):130-5. doi: 10.5966/sctm.2014-0254. Epub 2015 Jan 9. Review.

10.

The early career researcher's toolkit: translating tissue engineering, regenerative medicine and cell therapy products.

Rafiq QA, Ortega I, Jenkins SI, Wilson SL, Patel AK, Barnes AL, Adams CF, Delcassian D, Smith D.

Regen Med. 2015 Nov;10(8):989-1003. doi: 10.2217/rme.15.56. Epub 2015 Dec 2. Review.

PMID:
26628407
11.

Emerging Translation of Regenerative Therapies.

Allickson JG.

Clin Pharmacol Ther. 2017 Jan;101(1):28-30. doi: 10.1002/cpt.549. Epub 2016 Nov 26.

PMID:
27806427
12.

Innovative regenerative medicines in the EU: a better future in evidence?

Corbett MS, Webster A, Hawkins R, Woolacott N.

BMC Med. 2017 Mar 8;15(1):49. doi: 10.1186/s12916-017-0818-4.

13.

A systematic review of factors influencing decision-making in adults living with chronic kidney disease.

Murray MA, Brunier G, Chung JO, Craig LA, Mills C, Thomas A, Stacey D.

Patient Educ Couns. 2009 Aug;76(2):149-58. doi: 10.1016/j.pec.2008.12.010. Epub 2009 Mar 25. Review.

PMID:
19324509
14.

Decisional needs assessment of patients with complex care needs in primary care: a participatory systematic mixed studies review protocol.

Bujold M, Pluye P, Légaré F, Haggerty J, Gore GC, Sherif RE, Poitras ME, Beaulieu MC, Beaulieu MD, Bush PL, Couturier Y, Débarges B, Gagnon J, Giguère A, Grad R, Granikov V, Goulet S, Hudon C, Kremer B, Kröger E, Kudrina I, Lebouché B, Loignon C, Lussier MT, Martello C, Nguyen Q, Pratt R, Rihoux B, Rosenberg E, Samson I, Senn N, Li Tang D, Tsujimoto M, Vedel I, Ventelou B, Wensing M; Participatory Review Team.

BMJ Open. 2017 Nov 12;7(11):e016400. doi: 10.1136/bmjopen-2017-016400.

15.

Concise review: cell therapy and tissue engineering for cardiovascular disease.

Haraguchi Y, Shimizu T, Yamato M, Okano T.

Stem Cells Transl Med. 2012 Feb;1(2):136-41. doi: 10.5966/sctm.2012-0030. Epub 2012 Jan 26. Review.

16.

Preclinical Toxicity Studies for Regenerative Medicine in Japan.

Shigeto J, Ichiki T, Nii T, Konno K, Nakanishi Y, Sugiyama D.

Clin Ther. 2018 Nov;40(11):1813-1822. doi: 10.1016/j.clinthera.2018.09.007. Epub 2018 Oct 24. Review.

PMID:
30458928
17.

Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine.

Ratcliffe E, Thomas RJ, Williams DJ.

Br Med Bull. 2011;100:137-55. doi: 10.1093/bmb/ldr037. Epub 2011 Aug 17. Review.

PMID:
21852279
18.

Regenerative medicine: future impact on clinical therapies and society.

Kargul J, Laurent GJ, Irminger-Finger I.

Int J Biochem Cell Biol. 2014 Nov;56:1. doi: 10.1016/j.biocel.2014.10.016. Epub 2014 Oct 16. No abstract available.

PMID:
25461768
19.

Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration.

Emmert MY, Hitchcock RW, Hoerstrup SP.

Adv Drug Deliv Rev. 2014 Apr;69-70:254-69. doi: 10.1016/j.addr.2013.12.004. Epub 2013 Dec 27. Review.

PMID:
24378579
20.

Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.

Bertram TA, Tentoff E, Johnson PC, Tawil B, Van Dyke M, Hellman KB.

Tissue Eng Part A. 2012 Nov;18(21-22):2187-94. doi: 10.1089/ten.TEA.2012.0186. Epub 2012 Sep 27.

PMID:
22838399

Supplemental Content

Support Center